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Summary
Background: Trends in cancer mortality for the elderly have
long been unfavourable.
Materials and methods: Mortality from 12 major cancer
sites, plus total cancer mortality at age 65-84 in 23 European
countries, the US and Japan was analyzed.
Results: Between the late 1980s and the late 1990s total
cancer mortality at age 65 to 84 has been declining in the
European Union (UE) (-5.5% in males. -4 .5% in females), in
United States (US) males (-2.3%), but not females (+4.4%),
and in Japanese females (-5.6%), but not males (+6.3%).
Cancer mortality in the elderly rose for both sexes in eastern
Europe. Gastric cancer mortality declined in all the areas.
Lung cancer rates declined over the last decade by 8.5% in
males in the EU, and by 0.9% in the US. Rates were still
increasing in eastern Europe, in Japanese males and in females
in all areas. Pancreatic mortality rates were increasing in both
sexes in the EU and Japan up to the late 1980s, and in eastern
Europe up to the 1990s, whereas rates for US males have been
declining over recent years. Breast cancer mortality has declined
over the last decade by 8% in the US and by 3%. in the EU,
while it has risen in eastern Europe and in Japan. Mortality
from breast and prostate as well as ovarian cancer remained
however low in elderly Japanese. Prostate cancer mortality
declined in the EU and in the US. whereas it rose in eastern
Europe and in Japan. Mortality from lymphomas and multiple
myeloma rose in both sexes and various geographic areas, but
improved diagnosis and certification may have played a role in
these trends. Mortality from leukemia in the elderly increased
in eastern Europe and Japan, but was stable in the US and the
EU.
Conclusions: Cancer mortality in the elderly has stopped
systematically rising, and is on the decline in males since the
late 1980s.
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From the late 1970s onwards, some decline in cancer
mortality has been reported in the United States (US)
[1-4] and western Europe [5-7]. However, trends in the
elderly population up to the early 1990s tended systemati-
cally to be less favourable [8-11]. This may be due to
a different cohort pattern of cancer mortality across
various generations and hence age groups [12], to more
substantial changes in diagnosis and certification accu-
racy of the elderly [11, 13], to a lower impact of earlier
diagnosis and improved treatment in the elderly [14, 15],
or to a contribution of various factors.
It is therefore important that recent trends in cancer
mortality in the elderly are monitored. Along this line,
we considered the mortality rate from cancers at 12
major sites up to 1998, plus the total cancer mortality
rate at age 65-84 in Europe, the US and Japan.
Materials and methods
Official death certification numbers for 23 European countries (the 15
countries of the European Union, plus eight others, but excluding
Albania and a few countries such as Andorra on Lichtenstein with a
population of < 1 million, the US and Japan were derived from the
World Health Organization (WHO) database. During the period
considered (1960-1998), three different Revisions of the International
Classification of Diseases (ICD) were used [16-18]. The classification
of cancer deaths were thus re-coded, for the entire period, according to
the Ninth Revision (ICD-9 [17]) Data were considered for total cancer
mortality, plus the specific data for 12 cancers which have specific
relevance for the elderly (i.e. mouth or pharynx, stomach, intestines,
pancreas, lung, female breast, ovary, prostate, kidney. non-Hodgkin's
lymphomas. multiple myeloma, and leukemias). To improve compara-
bility of data throughout different countries and periods, we pooled
together all intestinal sites including rectum.
In graphical form, trends are presented for the European Union,
including Austria. Belgium. Denmark, Finland, France. Germany.
Greece. Ireland. Italy. Luxembourg. The Netherlands. Portugal. Spain.
Sweden, and the United Kingdom, six eastern European countries
providing meaningful and comparable data since 1960 (Bulgaria.
Czech Republic. Hungary. Poland, Romania and Slovakia), the US
and Japan.
Estimates of the resident population, generally based on official
censuses, were obtained from ihe same WHO databank. From the
matrices of certified deaths and resident populations, age-specific rates
for each five-year age group considered (65-69 to 80-84) and period
were computed. Age-standardized rates were based on the world
standard population [19].
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Results
Figure 1 indicates the trends in age-standardized mortal-
ity at age 65 to 84 from all cancers and those occurring
at the 12 selected cancer sites in the EU, eastern Euro-
pean countries, the US and Japan over the period 1960—
1997. Most of the following comments, however, refer to
the trends observed over the last decade, i.e. between
1985-1989 and 1995-1998.
After earlier increases, total cancer mortality at age
65 to 84 has been declining in the EU (from 1457 of
100,000 in 1985-1989 to 1378/100,000 males in 1995-
1998, -5.5%; from 712 to 690/100,000 females, -4.5%),
in US males (from 1266 to 1237, -2.3%), but not females
(from 732 to 764, +4.4%), and in Japanese females (from
557 to 526/100,000, -5.6%), but not males (from 1218 to
1295, +6.3%). Cancer mortality in the elderly rose for
both sexes in eastern Europe (from 1294 to 1359 for
males, +5.1%; from 669 to 688 for females, +2.7%).
Oral cancer mortality in the elderly was approximately
stable in the EU, with rates around 30/100,000 males
and 5/100,000 females. Rates steadily rose for males in
eastern Europe, to reach 32/100,000 in the late 1990s. In
the US, rates have been moving downwards for males
since the late 1970s, and moderately upwards for females
up to the late 1990s. An appreciable rise was observed
for Japanese males over the last few years.
Gastric cancer mortality steadily declined in all the
areas considered, and the fall was proportionally larger
in the EU (about 30% in both sexes) as compared to
eastern Europe (23%), the US (-19% in males, -17% in
females) or Japan (-19% in males, - 3 1 % in females).
Rates in Japan, moreover, were six to eight times higher
than in the US, whereas those in Europe were inter-
mediate.
Colorectal cancer rates in the elderly, after earlier
increases, declined over the last decade in both sexes in
the EU (-11% for males, -20% for females), and the US
(-16% for males, -18% for females), but rose in eastern
Europe (+16% in males; +4% in females), and in Japan,
mostly in males (+23% for males, +4% for females). In
1995-1998 intestinal cancer rates for Japanese males
(135/100,000) were higher than in the US (124/100,000),
while the rate in the EU was 152/100,000, and that in
eastern Europe 175/100,000.
Pancreatic cancer mortality rose in the elderly of both
sexes in the EU and Japan up to the late 1980s and
levelled off thereafter - at higher levels (70/100,000) for
males in Japan. Rates have been moving steadily up-
wards for both sexes in eastern Europe, and moderately
upwards in women, but downwards in males in the
USA.
After substantial rises between 1960 and 1985, lung
cancer rates at age 65 to 84 for the first time declined
over the last decade, by 8.5% in males in the EU, and by
0.9% in the US. Rates were still increasing in eastern
European (+6%) and Japanese males (+12%) and in
females in all areas (+16% in the EU, +24% in eastern
Europe, +36% in the US, but only +1.2% in Japan).
While in elderly men the differences in lung cancer rates
across broad geographic areas were relatively limited, in
women an approximately three-fold difference was still
evident between the rates of 67-77/100,000 in Japan and
Europe, and the rates of 212/100,000 in the US.
Again after earlier rises in most areas, breast cancer
mortality in women aged 65 to 84 declined by 8% in the
US and by 3% in the EU, to reach 106/100,000 in both
areas, while rose from 80 to 90/100,000 in eastern
Europe, and from 19 to 24/100,000 in Japan.
Ovarian cancer mortality in elderly women has been
steadily increasing both in the EU and in eastern Euro-
pean countries. Trends tended in contrast to level off in
the US and Japan over the last few years, although
mortality rates were higher in the USA and much lower
in Japan.
Prostate cancer mortality in males aged 65 to 84
declined by 4% in the EU and 6% in the US, to reach
the same value of 149/100,000 for both areas. In eastern
Europe, prostate cancer mortality rose from 113 to 127/
100,000 (+13%). In Japan, prostate cancer mortality
started from appreciably lower levels and over the last
decade rose by 33%, from 36 to 48/100,000.
Kidney cancer mortality in the elderly of both sexes
steadily and appreciably increased in all geographic
areas considered. Absolute rates, however, were con-
siderably higher in Europe, and particularly eastern
Europe (48.4/100,000 males, 23.1/100,000 females),
than in the USA and, for the most part, in Japan.
Mortality from non-Hodgkin's lymphoma in the
elderly showed an upward trend in all the geographic
areas considered, although the absolute rates were dif-
ferent and the presence of major changes in the slopes
suggests that the criteria of diagnosis and classification
for this heterogeneous group of neoplasms have prob-
ably changed over time. In the late 1990s, absolute rates
were higher in the US (47/100,000 males, 33/100,000
females) than in the EU (31/100,000), and even lower in
Japan and eastern Europe.
Mortality from multiple myeloma at age 65 to 84
steadily rose by 10% to 20% in both sexes in all geo-
graphic areas considered.
Up to the last few years, mortality from leukemia in
the elderly tended to rise in Japan and eastern Europe,
but has become relatively stable, although at high values
(45/100,000 males; 20/100,000 females) in the EU and
the USA (around 45/100,000 males; 23/100,000 females).
Some indication of a reversal in the trends has become
apparent in the EU in recent years.
Tables 1 (for males) and 2 (for females) give the
mortality rates from total cancer mortality and six
major cancer sites in 21 European countries (data were
not available for Belgium after 1994, and Luxembourg
was not included due to low absolute numbers), and
additionally for the US and Japan. Declines, though to
a different degree, were observed in France, Germany,
Italy and the UK for total cancer mortality in both sexes,
whereas rates were upwards in most eastern European
countries, and showed no consistent pattern in Spain,
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Figure I Trends in age-standardized (at age 65 to 84. world standard) death certification rates per 100.000 population from selected cancers or
groups of cancers in the EU, selected eastern European countries, USA and Japan, I960—1997.
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Figure 1. Continued.
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Figure I Continued.
Portugal and Greece. Lung cancer trends in elderly
males varied appreciably from country to country, with
a 25% fall in the UK, but not in other major European
countries. Lung cancer mortality was generally increas-
ing, though to varying degrees, for elderly females. A
substantial decline in breast cancer mortality (-14%)
was observed in the UK, whose rates were originally
higher, but not in other major European countries.
Prostate cancer rates moved downwards in France and
Italy, but upwards in most other countries. Mortality
from multiple myeloma was consistently upwards in
most European countries, except the UK, Finland, The
Netherlands and Norway. The Russian Federation had
the highest total cancer (1532/100,000) mortality in
elderly males, and some of the highest rates for most
sites, except breast and prostate. Over the last decade,
cancer mortality rates increased in elderly Russian by
7.4% in males and 5.5% in females.
Discussion
The main finding of this updated analysis of cancer
mortality in the elderly is the observation of a change in
the trends for males in the US and for both sexes in the
EU, with the consequent end of a long-term rise, and the
beginning of a measurable declining trend in males.
Some decline in total cancer mortality was observed
also for females in Japan. This is a new observation,
since declines in total cancer mortality have been regis-
tered in young [20, 21] and middle age, as well as in
overall age-standardized rates, but rates in the elderly
had longer been rising, and have been described as a
particularly unfavourable indicator of cancer mortality
[8-10].
In all the geographic areas considered, a component
of the falling rate has been the steady decline in gastric
cancer [22]. However, in the EU, and, more importantly,
in the US, gastric cancer rates were already low in the
1980s, and consequently this was a relatively minor
component of the global trends.
Of major relevance are the changing trends in lung
and other tobacco-related neoplasms, including pan-
creas, in the two sexes and various geographic areas.
Thus, lung cancer mortality rates in elderly males have
started levelling off in the EU (and substantially in the
UK [23] and in the US [3]). This reflects the decreased
prevalence of smoking in subsequent generations of
elderly males [24, 25], and the increased numbers of
people who have quit smoking. Lung cancer rates, in
contrast, have increased by 36% in US females, reaching
a rate of over 210/100,000, i.e. twice that of breast
cancer. The rise was 16% in the EU, with a rate of 77/
100,000. These unfavourable trends reflect the increased
prevalence of smoking in elderly women in the US [3]
and, to a lesser degree, Europe. Within Europe, female
rates in Denmark, Iceland and the UK approached 200/
100,000, as well [26]. Trends in mortality from oral
cancer reflect the pattern not only of tobacco but also
of alcohol consumption in the two sexes and various
areas of the world [12, 13].
An 8% fall in breast cancer mortality for elderly
women was registered in the US, and a 3% decrease in
the EU. These favourable trends reflect advancements in
screening, early diagnosis, and treatment of breast can-
cer [27-30], although the declines are smaller than the
15% to 20% reported for younger women (aged 50 to
70 [31]), thus raising questions about modifying the
diagnosis and treatment approaches to breast cancer in
elderly women.
Table I Trends in age-standardized (65-84 years, world standard) death certification rates per 100.000 men from five major cancers plus total mortality in various countries between 1985-1989 and 1995-1998
(unless otherwise mentioned in parenthesis).
Country
Austria
Bulgaria
Czech Republic
Denmark (1995-1996)
Finland (1995- 1996)
France(1995-1997)
Germany
Greece (1995-1997)
Hungary
Ireland (1995-1996)
Italy (1995-1996)
The Netherlands (1995-1997)
Norway (1995-1996)
Poland (1995-1996)
Portugal
Romania
Russian Federation (1995-1997)
Spain (1995-1997)
Sweden (1995-1996)
Switzerland (1990-1994)
United Kingdom (1995-1997)
European Union (1995-1997)
USA (1995-1997)
Japan(1995-1997)
Stomach
1985-
1989
162.1
163.0
170.7
70.1
124.2
81.9
137.7
78.4
204.4
117.2
163.0
119.9
104.0
205.2
197.1
143.5
309.2
123.8
84 7
88 3
122.2
126.9
40.6
304.5
1995-
1998
103 9
117.9
1116
49 5
78.9
56 2
95.2
66 5
156.6
84 5
113.0
81.8
76.8
151.9
159.8
123.7
247 9
95 3
55 8
l i t
80 5
90.1
32.7
245 9
%
change
-35 9
-27 7
-34 6
-29 4
-36 5
-31 4
-30.9
-15.2
-23.4
-27.9
-30 7
-31.8
-26.2
-26.0
-18.9
-13.8
-19 8
-23 0
-34 1
-166
-34.1
-29.0
-19 5
-192
Intestines
1985-
1989
195.5
119.0
305 5
202.4
1130
187 5
187.9
72.4
229.6
209 4
160 6
175 1
169 1
1152
143.7
72.6
135.3
119.7
131.4
167.4
178.6
170.5
147.8
109.6
1995-
1998
178.6
140.5
292.8
198.9
101.1
143.6
175.9
71.5
293.3
188 9
137 3
161.5
168 6
143 4
156.3
96.0
153.1
139.1
123.4
154.8
151.7
151.7
123.9
135.1
%
change
-8 6
18.1
-4.2
-1 7
-10 5
-23 4
-6.4
-1 2
27.7
-9 8
-14.5
-7 8
-0.3
24 5
8 8
32 2
13.2
16.2
-6.1
-7.5
-15.1
-11.0
-16.2
23.3
Lung
1985-
1989
353.8
219.4
520 9
464.8
457.3
323 6
387 4
381.6
460.6
424.7
439.2
678.1
251.2
435.5
178.2
175.9
445.3
328 6
199 2
384.3
550.8
423.8
440.6
273 4
1995-
1998
321.2
211.8
468.1
440.4
385.9
326.6
368.0
392 3
534 3
389.3
441.0
548.4
278 6
508 9
2173
226 5
457.3
365 5
191.8
358 2
414.5
387.6
436.7
305.2
%
change
-9.2
-3 5
-10.1
-5.2
-15.6
0 9
-5 0
2 8
160
-8.3
0.4
-19.1
109
169
21 9
28 8
2.7
11 2
-3 7
-6 8
-24 7
-8.5
-0.9
11.6
Prostate
1985-
1989
165.9
81 0
162.9
182.7
162.7
170.1
158.5
81.8
164 5
176 0
121.2
168.8
218.7
102.3
137 5
76 8
66.1
131.5
199 4
217.4
160 6
155 1
158.4
36.3
1995-
1998
157 3
91 6
166 9
209.1
181.1
142 3
155 9
96 5
177 5
197.3
107.2
177.4
229.9
120.8
172 7
91.2
78.0
131.5
221 1
220.7
161 5
149 5
148 9
48.1
change
-5 2
13 1
2 5
144
11 3
-16.3
1 6
18.0
7.9
12.1
-11.6
5.1
5.1
18.1
25.6
18.8
18.0
0.0
10.9
1.5
0.6
-3.6
-6.0
32.5
Multiple
1985-
1989
132
2 8
152
21 7
25 6
17 2
164
10.4
11.2
27.1
16.2
25.2
31.7
9.7
13.4
22.1
21.7
21.8
17.8
21.8
10.2
myeloma
1995-
1998
170
2.1
18.9
26 3
20.5
17.7
19.6
12.1
15.6
27.0
18.1
25.4
28.8
15.8
17.2
23.2
24.8
21 1
19.6
23.9
12.5
%
change
28.8
-25 0
24 3
21.2
199
2 9
19.5
16.3
39.3
0 4
11 7
0 8
-9 1
62.9
28 4
5 0
14.3
-3.2
10.1
9.6
22.5
Total, all
1985-
1989
1373 0
870 7
1749 2
1500 9
1330.0
1479.2
1420.1
1128.7
1636.8
1434.2
1498.5
1679.9
1230.2
1380 5
1035 4
792.8
1426.5
1258.1
1082.3
1434.8
1536.5
1457.2
1265.5
1218.0
sites
1995-
1998
1263.8
884.4
1674.8
1516.5
1234.0
1370 2
1345 3
1160 0
1835.1
1427.4
1437.9
1535.9
1251 6
1511 6
1171 9
917 7
1531.6
1306 7
1051 6
1365 2
1375 3
1377 5
1236.7
1294.7
%
change
8.0
1.6
4.3
1 0
7.2
7 4
5.3
2 8
12 1
0.5
-4.0
-8 6
1 7
9.5
132
15.8
7.4
3.9
-2 8
- 4 9
-10 5
-5 5
-2.3
6.3
Table 2. Trends in age-standardized (65-84 years, world standard) death certification rates per 100,000 women from five major cancers plus total mortality in various countries between 1985-1989 and 1995—
1998 (unless otherwise mentioned in parenthesis).
Country
Austria
Bulgaria
Czech Republic
Denmark (1995-1996)
Finland (1995-1996)
France(1995-1997)
Germany
Greece (1995-1997)
Hungary
Ireland (1995-1996)
Italy (1995-1996)
The Netherlands (1995-1997)
Norway (1995-1996)
Poland (1995-1996)
Portugal
Romania
Russian Federation (1995-1997)
Spain (1995-1997)
Sweden(1995-1996)
Switzerland (1990-1994)
United Kingdom (1995-1997)
European Union (1995-1997)
USA (1995-1997)
Japan(1995-1997)
Stomach
1985-
1989
91.4
91.3
81.4
32 4
63.3
32 0
66 0
43.0
86.0
52.5
74.3
44.0
43 9
74 3
95 2
60.7
141.8
58.8
37 6
37 3
48 7
57.0
17.7
1183
1995-
1998
61.2
62.9
52 8
21.4
40.4
20.1
45 9
34 4
65.8
37.9
54.9
30.3
32.8
56.9
71 4
51 4
108 4
40 0
26.4
30.1
31.7
39.2
14.7
81 3
%
change
-33.0
-31 1
-35.1
-34.0
-36.2
-37.2
-30 5
-20.0
-23.5
-27.8
-26.1
-31.1
-25.3
-23 4
-25 0
-15 3
-23 6
-32 0
-29.8
-19.3
-34.9
-31.2
-16.9
-31.3
Intestines
1985-
1989
119.1
76.3
167 8
140.9
78.0
101 1
135 9
59 7
151.3
128.4
102.4
119.3
1109
79 6
91.5
53 6
87 2
78.3
89.0
94.2
117 1
1120
98 6
67 9
1995
1998
98 3
84 1
140.9
131.0
67.6
74.6
113.3
48.7
154 9
103 1
75 5
103.0
113.5
92.3
79.8
61.8
94.9
74.9
83.5
85 0
91.7
89.9
80.7
70 4
%
change
-17.5
10.2
-16.0
-7.0
-13 3
-26 2
-16.6
-18.4
2.4
-19 7
-26.3
-13.7
2.3
16.0
-12.8
15.3
8.8
-4.3
-6.2
-9.8
-21 7
-197
-18.2
3.7
Lung
1985-
1989
60 6
42 6
54 9
137 3
50 2
32 4
50.3
48.5
80.3
144.0
52.7
50.7
57.5
57.2
26 6
35.7
52.3
25.5
60.0
45.8
158.1
66.5
155.1
66 3
1995-
1998
70.5
41.9
78.4
197.9
54 5
41 0
66.8
51.1
113.7
160.4
60.8
89.3
95.6
71.8
28.5
45.2
49.3
25.7
82 9
53.9
180 7
77 4
211 6
67.1
%
change
16.3
-1.6
42.8
44.1
8 6
26.5
32.8
5.4
41.6
11.4
15.4
76 1
66.3
25.5
7.1
26.6
-5.7
0.8
38.2
17 7
143
164
36.4
1 2
Breast
1985-
1989
117.0
66.9
115 3
139 5
84 8
99 0
109.5
69.3
111.7
122.8
100.2
136.1
99.7
70.3
71.9
59.9
50.0
71.7
93 1
138.0
144.0
109.6
115.7
19.0
1995-
1998
106.5
71.3
1166
151 5
79 1
98 9
110.3
83.5
122.5
129.7
100.0
133.4
98.8
77.8
81.9
70.9
67.7
77 3
89 0
131.1
123.4
106.0
106.2
24.4
%
change
-9.0
66
1 1
8.6
-6.7
-0.1
0.7
20.5
9.7
5.6
-0.2
-2.0
-0.9
10.7
13.9
18.4
35.4
78
-4.4
-5.0
-14.3
3.3
-8 2
28 4
Multiple
1985-
1989
11.1
1.5
11.7
14.7
17.4
12.2
11.0
7.9
9.3
18.4
11.7
16.2
19.0
7.3
9.8
15.7
15.4
14 9
123
14.9
7.2
myeloma
1995-
1998
14.7
1.7
129
165
193
123
13.8
8.8
11.9
16.8
13.0
17.0
18.4
11.9
12.8
17.2
15.7
14.5
13.9
16.5
8.5
%
change
32.4
13.3
10.3
12.2
10.9
0.8
25.5
11.4
28.0
-8.7
11.1
4.9
-3.2
63 0
30.6
96
1 9
-2 7
130
10.7
18.1
Total,
1985-
1989
762.7
497 1
871.9
906 3
654 1
602 7
767.4
521.7
855.3
839.3
682.3
724.1
667.8
674.7
531.6
460.3
605 7
540 9
673 5
695 0
850.9
712.2
731.8
557.2
all sites
1995-
1998
687.0
492.9
851 5
980.4
611 6
567 2
722.5
535.4
900.7
853.5
646.2
729.9
709.7
706.2
544.9
497.9
639.3
522.0
685 9
669.4
835 7
680.0
764.1
525.9
%
change
-9.9
-0 8
-2 3
82
-6 5
-5.9
-5.9
2.6
5.3
1 7
-5.3
0.8
6.3
4.7
2.5
82
5.5
-3 5
1 8
-3 7
-1 8
-4.5
4.4
-5.6
1476
A similar line of reasoning applies to prostate cancer
in the EU and US [32, 33]. The decrease in prostate
cancer mortality may at least in part be attributed to a
favourable influence of prostate specific antigen (PSA)
testing. This was introduced in Western Europe a few
years later than in the USA, and the proportion of men
aged 65 or over who have undergone PSA testing is
probably much lower in Europe than in several areas of
the US [32, 33]. This is compatible with the smaller
decline in mortality in the EU than in the USA. In any
case, the first observation of favourable changes in
trends for mortality from these common cancers in the
elderly is extremely encouraging. Mortality from breast
and prostate cancer in the elderly was still rising in
Japan, but absolute rates remained comparatively low
[34].
In addition, ovarian cancer rates were low in Japan,
and showed only a moderate tendency to rise over the
last few years, whereas a steady upward trend was still
evident in Europe. The leveling off in the US may also
reflect the favorable impact of oral contraceptives on the
risk of ovarian cancer in the elderly [35].
It is more difficult to explain the levelling trends and
the declines in colorectal cancer mortality, particularly
in elderly women. These tendencies may also be due, at
least in part, to earlier diagnosis, but a more favourable
pattern of risk factor exposure (including diet and per-
haps hormones for women [36, 37] has probably played
some role as well.
Mortality from kidney cancer and, more importantly,
from multiple myeloma has, in contrast, been steadily
rising in most countries considered, with the notable
exceptions of some northern European countries (i.e.,
Finland, Norway and Sweden). Diagnostic improve-
ments still partly or largely account for these trends, but
it is also possible that some real increase has occurred in
incidence and mortality from myelomas [38], as well as
for lymphomas [39], which have also been increasing in
most areas, without there being any obvious explana-
tions and consistent patterns. Brain cancer is another
form of the disease that has risen in the elderly, but the
WHO database did not provide enough information to
understand and evaluate brain cancer trends in various
countries [40, 41]. Mortality from leukemia in the elderly,
in contrast, tended to remain at the same level over the
last decade, possibly reflecting improvements in manage-
ment and treatment of the disease in the elderly, though
to a lower degree than has occured in younger aged
patients [42].
In general, it is important to stress the limitations and
uncertainties of cancer death certification for the elderly
and their trends over time. Although the exact influence
of increasingly more accurate certification on cancer
rates remains undefined, almost certainly this has
caused some systematic upward trends over time, fol-
lowing the generalized improvement in diagnosis and
certification of selected cancer sites, especially prostate
and multiple myeloma [11, 13, 40].
Within Europe, a substantial variation in mortality
from several major cancer sites can still be observed in
the elderly, although for other neoplasms - such as
breast or prostate - tendencies towards stabilizing were
also apparent [43]. Most trends remain unfavourable for
the elderly population of both sexes in eastern Europe,
reflecting both rising trends in underlying incidence -
due to unfavourable patterns in smoking, characteristics
of diet and exposures to other risk factors, and to
systematic delay in the adoption of improved diagnosis
and treatment methods. Thus, while stomach cancer
rates remain high in these areas of the continent, lung
cancer rates in males have reached some of the highest
rates observed (over 500/100,000 in Hungary or
Poland), and breast or prostate cancer rates were still
moving upwards. Comprehensive intervention for cancer
control among elderly, particularly in eastern Europe, is
therefore a public health priority [44-47].
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